A Real Breakthrough; New Formula,
What people say makes us excited::
Yes, I DID receive your new formula. Sorry I didn't
respond sooner, but I took some time off and went
away for a long weekend.
I am VERY impressed with the sample you sent.
I
have used it about six times now, and I have really
experienced great relief...more than any other product that I have tried so far! So, I am very happy to pass that news along to you. And, I am also very happy to have found a product that works.
It seems to work almost immediately. The smell as well as the color is much more pleasant than your last formula, too.
Congratulations on a very fine product!!
You must be very excited to share this with people.
Sincerely,
Mary Selfridge
Sabin/GW Researchers Clear First Hurdle with Investigational New Drug Approval
WASHINGTON, Jan. 26 /PRNewswire/ -- Clinical trials to test the safety of
a first-of-its-kind human hookworm vaccine will begin in the Washington, DC
area in a couple of months after the U.S. Food and Drug Administration
conferred investigational new drug status on the vaccine. No current vaccine
is available to prevent hookworm disease, which is one of the most common
chronic infections of humans with an estimated 740 million cases in areas of
rural poverty in the tropics and subtropics.
The Human Hookworm Vaccine Initiative is sponsored by the Albert B. Sabin
Vaccine Institute, and is funded by the Bill & Melinda Gates Foundation. The
research is conducted at The George Washington University Medical Center.
Peter J. Hotez, MD, PhD, professor and chair of GW's Department of
Microbiology and Tropical Medicine leads the scientific team and has been
responsible for the development of the vaccine. "Approval to begin safety
trials is a major milestone for the human hookworm vaccine project," Hotez
said. "It has taken an amazing amount of our team's effort to get us to the
current stage of vaccine development. Of course, our ultimate goal is to take
this research to developing countries where the vaccine will be tested in
individuals who suffer from hookworm infection."
Human hookworm infection is caused by parasitic worms that fasten onto the
inner layers of the small intestine using their teeth-like projections and
cause blood loss at the attachment site. Hookworm disease refers to the iron
deficiency anemia that results from moderate and heavy infections. Because
women and young children have the lowest iron stores, they are the most
vulnerable to chronic hookworm blood loss. In children, chronic hookworm
disease contributes to physical growth retardation and cognitive impairment.
Hookworm is considered a major health threat to adolescent girls, women of
reproductive age, and to outcomes in pregnancy and is a major contributor to
misery and suffering in the poorest of the poor.
This first phase of clinical research will assess the initial safety of
the new hookworm vaccine, as well as the immune system's response to
vaccination. Several more years of subsequent research on the vaccine's
effect will be required before it can be licensed for use. Looking towards the
future, the Sabin Vaccine Institute signed a memorandum of understanding this
past fall with federal and state vaccine production facilities in Brazil for
clinical development of the vaccine. A Human Hookworm Vaccine Initiative team
based in Brazil is now assembling baseline data in a rural area impacted by
hookworm disease. In just more than a year, that data and data from safety and
tolerability trials in the United States, will serve as required groundwork
for a wider clinical trial, to ascertain the efficacy and safety of the new
vaccine.
The Human Hookworm Vaccine Initiative of the Sabin Vaccine Institute and
the Bill & Melinda Gates Foundation is being conducted at The George
Washington University Medical Center. For more information, visit
http://www.sabin.org.
